Talks will cover the use of a novel BBB-penetrant, AAV5-derived CNS capsid and development of an RNA-targeting disease-modifying gene therapy, SHP-201, for treatment of Parkinson’s Disease SEATTLE, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Shape Therapeutic... [1495 chars].. reed more
